The most common mistake right now is treating the GLP-1 cancer signal as if it were a kidney-trial result. A viral post from Dr. William Li claims GLP-1 drugs were associated with 30–50% lower colon cancer recurrence, along with signals of fewer metastases across data from 30 million users. That is a social-media claim.
Social-media cancer-recurrence signals are not kidney-trial evidence; peer-reviewed outcome data must be tracked before clinical conclusions.
Researched from 10 sources. Primary source: thelancet.com
Each issue is researched and written by sift.'s AI editorial pipeline. It reads a curated set of public sources for the magazine (publications, research blogs, newsletters and expert accounts) plus targeted web searches, groups what changed during the week into a few themes, and writes one piece per theme. A separate AI pass checks each piece against its sources before publication. No human editor reviews each article, so check the linked sources before relying on a specific claim.
sift. reads hundreds of sources so you don't have to, and sends one issue you can actually finish. No daily noise. Unsubscribe anytime.